Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Geannyne Villegas-Rivera, Luis Miguel Román-Pintos, Ernesto Germán Cardona-Muñoz, Oscar Arias-Carvajal, Adolfo Daniel Rodríguez-Carrizalez, Rogelio Troyo-Sanromán, Fermín Paul Pacheco-Moisés, Aldo Moreno-Ulloa, Alejandra Guillermina Miranda-Díaz, Geannyne Villegas-Rivera, Luis Miguel Román-Pintos, Ernesto Germán Cardona-Muñoz, Oscar Arias-Carvajal, Adolfo Daniel Rodríguez-Carrizalez, Rogelio Troyo-Sanromán, Fermín Paul Pacheco-Moisés, Aldo Moreno-Ulloa, Alejandra Guillermina Miranda-Díaz
Abstract
Objective: To evaluate the effects of ezetimibe/simvastatin (EZE/SIMV) and rosuvastatin (ROSUV) on oxidative stress (OS) markers in patients with diabetic polyneuropathy (DPN).
Methods: We performed a randomized, double-blind, placebo-controlled phase III clinical trial in adult patients with Type 2 Diabetes Mellitus (T2DM) and DPN, as evaluated by composite scores and nerve conduction studies (NCS). Seventy-four subjects with T2DM were allocated 1 : 1 : 1 to placebo, EZE/SIMV 10/20 mg, or ROSUV 20 mg for 16 weeks. All patients were assessed before and after treatment: primary outcomes were lipid peroxidation (LPO), and nitric oxide (NO) surrogate levels in plasma; secondary outcomes included NCS, neuropathic symptom scores, and metabolic parameters. Data were expressed as mean ± SD or SEM, frequencies, and percentages; we used nonparametric analysis.
Results: LPO levels were reduced in both statin arms after 16 weeks of treatment (p < 0.05 versus baseline), without changes in the placebo group. NO levels were not significantly affected by statin treatment, although a trend towards significance concerning increased NO levels was noted in both statin arms. No significant changes were observed for the NCS or composite scores.
Discussion: EZE/SIMV and ROSUV are superior to placebo in reducing LPO in subjects with T2DM suffering from polyneuropathy. This trial is registered with NCT02129231.
Figures
References
- Dyck P. J., Kratz K. M., Karnes J. L., et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester diabetic neuropathy study. Neurology. 1993;43(4):817–824. doi: 10.1212/wnl.43.4.817.
- Kamenov Z. A., Traykov L. D. Diabetic somatic neuropathy. Advances in Experimental Medicine & Biology. 2012;771:155–175.
- Dyck P. J. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle & Nerve. 1988;11(1):21–32. doi: 10.1002/mus.880110106.
- Dyck P. J., Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. Journal of Neuropathology & Experimental Neurology. 1996;55(12):1181–1193. doi: 10.1097/00005072-199612000-00001.
- Vincent A. M., Brownlee M., Russell J. W. Oxidative stress and programmed cell death in diabetic neuropathy. Annals of the New York Academy of Sciences. 2002;959:368–383.
- Vincent A. M., Russell J. W., Low P., Feldman E. L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrine Reviews. 2004;25(4):612–628. doi: 10.1210/er.2003-0019.
- Russell J. W., Golovoy D., Vincent A. M., et al. High glucose-induced oxidative stress and mitochondrial dysfunction in nuerons. The FASEB Journal. 2002;16(13):1738–1748. doi: 10.1096/fj.01-1027com.
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine. 1993;329(14):977–986. doi: 10.1056/NEJM199309303291401.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. The Lancet. 1998;352(9131):837–853.
- Ismail-Beigi F., Craven T., Banerji M. A., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. The Lancet. 2010;376(9739):419–430. doi: 10.1016/s0140-6736(10)60576-4.
- Vincent A. M., Hinder L. M., Pop-Busui R., Feldman E. L. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. Journal of the Peripheral Nervous System. 2009;14(4):257–267. doi: 10.1111/j.1529-8027.2009.00237.x.
- Wiggin T. D., Sullivan K. A., Pop-Busui R., Amato A., Sima A. A. F., Feldman E. L. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58(7):1634–1640. doi: 10.2337/db08-1771.
- Girach A., Manner D., Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. International Journal of Clinical Practice. 2006;60(11):1471–1483. doi: 10.1111/j.1742-1241.2006.01175.x.
- Pande M., Hur J., Hong Y., et al. Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: a model of type 2 diabetes. Diabetes. 2011;60(7):1981–1989. doi: 10.2337/db10-1541.
- Taylor F., Huffman M. D., Macedo A. F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2013;1CD004816
- Liao J. K., Laufs U. Pleiotropic effects of statins. Annual Review of Pharmacology & Toxicology. 2005;45:89–118. doi: 10.1146/annurev.pharmtox.45.120403.095748.
- Davis T. M. E., Yeap B. B., Davis W. A., Bruce D. G. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008;51(4):562–566. doi: 10.1007/s00125-007-0919-2.
- Franzoni F., Quiñones-Galvan A., Regoli F., Ferrannini E., Galetta F. A comparative study of the in vitro antioxidant activity of statins. International Journal of Cardiology. 2003;90(2-3):317–321. doi: 10.1016/s0167-5273(02)00577-6.
- Grosser N., Erdmann K., Hemmerle A., et al. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochemical and Biophysical Research Communications. 2004;325(3):871–876. doi: 10.1016/j.bbrc.2004.10.123.
- Resch U., Tatzber F., Budinsky A., Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. British Journal of Clinical Pharmacology. 2006;61(3):262–274. doi: 10.1111/j.1365-2125.2005.02568.x.
- England J. D., Gronseth G. S., Franklin G., et al. Distal symmetric polyneuropathy: a definition for clinical research—report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64(2):199–207. doi: 10.1212/01.wnl.0000149522.32823.ea.
- Callaghan B. C., Cheng H. T., Stables C. L., Smith A. L., Feldman E. L. Diabetic neuropathy: clinical manifestations and current treatments. The Lancet Neurology. 2012;11(6):521–534. doi: 10.1016/s1474-4422(12)70065-0.
- Argoff C. E., Cole B. E., Fishbain D. A., Irving G. A. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clinic Proceedings. 2006;81(4, supplement):S3–S11. doi: 10.1016/s0025-6196(11)61176-2.
- Vinik A. I., Mehrabyan A. Diabetic neuropathies. Medical Clinics of North America. 2004;88(4):947–999. doi: 10.1016/j.mcna.2004.04.009.
- Clemens A., Siegel E., Gallwitz B. Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids—update on the background of the current guidelines. Experimental and Clinical Endocrinology and Diabetes. 2004;112(9):493–503. doi: 10.1055/s-2004-821306.
- Zangiabadi N., Shafiee K., Alavi K. H., Assadi A. R., Damavandi M. Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: a double blind, randomized clinical trial. Minerva Endocrinologica. 2012;37(2):195–200.
- Niki E. Lipid peroxidation products as oxidative stress biomarkers. BioFactors. 2008;34(2):171–180. doi: 10.1002/biof.5520340208.
- Halliwell B., Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. American Journal of Clinical Nutrition. 1993;57(5)
- Koksal M., Eren M. A., Turan M. N., Sabuncu T. The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. European Journal of Internal Medicine. 2011;22(3):249–253. doi: 10.1016/j.ejim.2010.12.003.
- Yoshino G., Tanaka M., Nakano S., et al. Effect of rosuvastatin on concentrations of plasma lipids, urine and plasma oxidative stress markers, and plasma high-sensitivity C-reactive protein in hypercholesterolemic patients with and without type 2 diabetes mellitus: a 12-week, open-label, pilot study. Current Therapeutic Research: Clinical & Experimental. 2009;70(6):439–448. doi: 10.1016/j.curtheres.2009.12.003.
- Girona J., La Ville A. E., Solà R., Plana N., Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. The American Journal of Cardiology. 1999;83(6):846–851. doi: 10.1016/s0002-9149(98)01071-6.
- Creager M. A., Lüscher T. F., Cosentino F., Beckman J. A. Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003;108(12):1527–1532. doi: 10.1161/01.cir.0000091257.27563.32.
- Liu P.-Y., Liu Y.-W., Lin L.-J., Chen J.-H., Liao J. K. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009;119(1):131–138. doi: 10.1161/circulationaha.108.813311.
- John S., Schneider M. P., Delles C., Jacobi J., Schmieder R. E. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. American Heart Journal. 2005;149(3):473.e1–473.e10. doi: 10.1016/j.ahj.2004.06.027.
- Koh K. K., Quon M. J., Han S. H., et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31(4):776–782. doi: 10.2337/dc07-2199.
Source: PubMed